RE:ValueExcluding the drugs in the bodies of some posters.... MCNA is the key product. Other drugs have been developed and marketed in the past but no longer part of Telesta's focus. Interesting to note that while MCNA is designed to target specifically Bladder cancer, it would make sense that other types of cancer could possibly be treated too. However, no studies that I know of have investigated this. For now all the focus is on MCNA's FDA submission in June. The stuff works, but will it be approved is the only question.... and therefore the valuation of this stock hinges primarily on FDA approval. One other thing; even if FDA approval is not successful, the drug does work, it just may need further development/study and that would be reason for a partnership/buyout as well....